It Could Be Time To Dump BHP Billiton plc And Buy AstraZeneca plc

BHP Billiton plc (LON: BLT) is struggling while AstraZeneca plc (LON: AZN) is making headway.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As BHP Billiton’s (LSE: BLT) share price slumps to new lows, one of the only things that’s keeping investors interested in the company is its 11.1% dividend yield. 

However, now that Glencore and Anglo American have suspended their dividend payouts to investors, BHP’s management is under pressure to do the same. 

The perfect storm

BHP is facing the perfect storm of events. The prices of all four of the company’s four ‘key pillar’ commodities are under pressure. Copper hit a new six-year low this week, coal and iron ore are both trading at (or close to) all-time lows and the price of oil continues to plunge. 

With no end to falling prices in sight, the writing is on the wall for BHP. Even if management doesn’t want to cut the company’s payout, its hand may be forced. BHP can only cut capital spending so far before operational efficiency starts to deteriorate and costs begin to rise. Also the company is facing a potential $3.5bn fine for its part in the Brazil dam disaster, which killed at least 13 people and devastated Brazil’s second-largest river system, the Rio Doce basin. 

And the figures show that BHP is already struggling to scrape together the cash needed to fund its dividend payout to shareholders. 

For example, the figures for BHP’s last financial year (ending June 2015) show that the company generated $19.3bn in cash from operations during the year. Capital spending for the year totalled $12.9bn, leaving $6.4bn for the dividend, which cost $6.5bn. Commodity prices have deteriorated since BHP reported these figures. 

A better investment

On the other hand, as BHP tries to navigate its way through all of these issues, AstraZeneca’s (LSE: AZN) outlook is only improving. 

Unlike BHP, Astra has control over the price of its products. BHP is forced to accept market rates for the commodities it mines, which makes it difficult to calculate a long-term valuation for the company and its assets. However, Astra’s management is quite upbeat about the company’s prospects and believes that the group has what it takes to return to growth by 2017. And this forecast has more weight behind it than any predictions about BHP’s future performance. 

Investing for growth

During the past 10 years, Astra has spent around $5bn per annum on R&D, that’s just under a fifth of revenues. The company now has more than 200 new products under development and City analysts believe that AstraZeneca’s treatment pipeline is robust enough to return the group to growth by 2017.

Analysts estimate that Astra’s new product sales could top $21bn – 90% of existing sales – by 2022 in a best-case scenario. Some of these products are already going through the final phases of testing, so to a certain extent Astra’s growth is de-risked and unlike BHP, investors don’t have to cross their fingers and hope iron ore prices recover. 

Then there’s Astra’s dividend yield to consider. The company’s shares currently support a dividend yield of 4.2% and the payout is covered one-and-a-half times by earnings per share, which leaves plenty of headroom if Astra’s growth is slower than expected. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »